Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
APG-1387 × 1 year × Clear all
NCT04284488 2026-01-08

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
40 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04643405 2026-01-08

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
21 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡